The project comprises construction of a shop for preparing human gene-engineering insulin substance with the capacity of 120 kg per year and a shop for preparing ready medicinal forms of 3 million bottles of insulin per year. Cost of the project is USD 112 million.
“Biopharminvest” (Russia) to create first in Russia commercial production of human gene-engineering insulin in Moscow region